Lisa H Lam1, Edmund V Capparelli2, Razelle Kurzrock3. 1. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, MC 0657, San Diego, La Jolla, CA, 92093-0657, USA. 2. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, MC 0657, San Diego, La Jolla, CA, 92093-0657, USA. ecapparelli@ucsd.edu. 3. Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, USA.
Abstract
PURPOSE: Acid-suppression therapy is known to decrease the systemic exposure of erlotinib. The erlotinib prescribing information recommends staggering dosing with a histamine-2 receptor antagonist (H2RA) and avoiding concurrent use of a proton pump inhibitor (PPI). This retrospective analysis evaluated the frequency of concurrent acid-suppression therapy in oncology patients receiving erlotinib and its association with outcomes. METHODS: All patients prescribed erlotinib within UC San Diego Health System between February 26, 2011, and February 28, 2014, were assessed for eligibility, survival outcomes and adverse events. RESULTS: Of the 76 patients in the analysis, 24 were prescribed both a PPI and an H2RA with erlotinib therapy (31.6 %). The two patient groups, with (n = 24) and without PPI/H2RA (n = 52), were similar in clinical characteristics and erlotinib dose. One patient received an H2RA therapy alone and was excluded from the analysis; no one received PPI therapy alone. Patients receiving erlotinib alone had a longer median progression-free survival (PFS) compared to patients with concurrent PPI/H2RA therapy (11.0 months vs. 5.3 months; P = 0.029). Overall survival (OS) and incidence of rash and/or diarrhea did not correlate with use of acid-suppression therapy. CONCLUSION: Nearly one-third of patients received acid-suppression therapy. Patients treated with erlotinib and PPI/H2RA therapy had shorter PFS, but similar OS and adverse event profile compared to those who did not receive acid-suppression.
PURPOSE: Acid-suppression therapy is known to decrease the systemic exposure of erlotinib. The erlotinib prescribing information recommends staggering dosing with a histamine-2 receptor antagonist (H2RA) and avoiding concurrent use of a proton pump inhibitor (PPI). This retrospective analysis evaluated the frequency of concurrent acid-suppression therapy in oncology patients receiving erlotinib and its association with outcomes. METHODS: All patients prescribed erlotinib within UC San Diego Health System between February 26, 2011, and February 28, 2014, were assessed for eligibility, survival outcomes and adverse events. RESULTS: Of the 76 patients in the analysis, 24 were prescribed both a PPI and an H2RA with erlotinib therapy (31.6 %). The two patient groups, with (n = 24) and without PPI/H2RA (n = 52), were similar in clinical characteristics and erlotinib dose. One patient received an H2RA therapy alone and was excluded from the analysis; no one received PPI therapy alone. Patients receiving erlotinib alone had a longer median progression-free survival (PFS) compared to patients with concurrent PPI/H2RA therapy (11.0 months vs. 5.3 months; P = 0.029). Overall survival (OS) and incidence of rash and/or diarrhea did not correlate with use of acid-suppression therapy. CONCLUSION: Nearly one-third of patients received acid-suppression therapy. Patients treated with erlotinib and PPI/H2RA therapy had shorter PFS, but similar OS and adverse event profile compared to those who did not receive acid-suppression.
Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316
Authors: Gillian S Smelick; Timothy P Heffron; Laura Chu; Brian Dean; David A West; Scott L Duvall; Bert L Lum; Nageshwar Budha; Scott N Holden; Leslie Z Benet; Adam Frymoyer; Mark J Dresser; Joseph A Ware Journal: Mol Pharm Date: 2013-10-24 Impact factor: 4.939
Authors: Michael P Chu; Sunita Ghosh; Carole R Chambers; Naveen Basappa; Charles A Butts; Quincy Chu; David Fenton; Anil A Joy; Randeep Sangha; Michael Smylie; Michael B Sawyer Journal: Clin Lung Cancer Date: 2014-08-15 Impact factor: 4.785
Authors: Mitesh J Borad; Kelly K Curtis; Hani M Babiker; Martin Benjamin; Raoul Tibes; Ramesh K Ramanathan; Karen Wright; Amylou C Dueck; Gayle Jameson; Daniel D Von Hoff Journal: J Cancer Date: 2012-08-17 Impact factor: 4.207
Authors: Angel A T Uchiyama; Pedro A I A Silva; Moisés S M Lopes; Cheng T Yen; Eliza D Ricardo; Taciana Mutão; Jefferson R Pimenta; Larissa M Machado; Denis S Shimba; Renata D Peixoto Journal: Curr Oncol Date: 2021-02-03 Impact factor: 3.677
Authors: Wilson Sim; Sneha Rajiv Jain; Wen Hui Lim; Yip Han Chin; Cheng Han Ng; Nicholas Syn; Kang Shiong Goh; Ross Soo; Lingzhi Wang; Boon Cher Goh Journal: Transl Lung Cancer Res Date: 2021-08
Authors: Deanna M Mudie; Stephanie Buchanan; Aaron M Stewart; Adam Smith; Kimberly B Shepard; Nishant Biswas; Derrick Marshall; Alyssa Ekdahl; Amanda Pluntze; Christopher D Craig; Michael M Morgen; John M Baumann; David T Vodak Journal: Int J Pharm X Date: 2020-02-19